Ezetimibe glucuronide competes with bilirubin for multidrug resistance-associated protein 2-mediated transport, thereby impairing bilirubin excretion and leading to isolated hyperbilirubinemia (Ritchie et al., 2008). This evidence concerns the gene ABCC2 and Hyperbilirubinemia.